Allay Therapeutics

Allay Tx is developing a drug-eluting biopolymer for sustained post-operative orthopedic pain management.
Menlo Park, CA

CEO: Adam Gridley
Arboretum lead: Paul McCreadie

April 11, 2024 in Allay Therapeutics, News Page

Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the results from a Phase 2B clinical study of its lead…
Read More
December 18, 2023 in Allay Therapeutics, Home Page, News Page

Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical

Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s…
Read More